摘要
目的分析中西医结合治疗小儿难治性肺炎支原体肺炎的安全性。方法选取我院2014年1月-2015年1月收治的小儿难治性肺炎支原体肺炎患儿72例,随机分为两组,对照组患者给予常规西医治疗,治疗组则采用中西医结合治疗,观察治疗的安全性。结果治疗后,治疗组C-反应蛋白、中性粒细胞比例及血沉等炎症指标水平,咳嗽、发热、肺部湿啰音等消失时间,临床总有效率,均优于对照组,差异有统计学的意义(P<0.05);但两组不良反应发生率比较差异无统计学意义(P>0.05)。结论给予小儿难治性肺炎支原体肺炎患儿中西医结合治疗的临床效果较为显著,且无明显不良反应,更为安全可靠,值得在临床上进一步推广应用。
Objective To analyze the safety of integrated Chinese and western medicine in the treatment of infantile refractory mycoplasmal penumoniae pneumonia( RMPP). Methods From January 2014 to January 2015 in the hospital,72 infantile RMPP were collected and randomized into two groups. In the control group,the routine western medicine was provided. In the treatment group,the integrated Chinese and western medicine was adopted. The safety of treatment was observed. Results After treatment,in the treatment group,the inflammatory index level,such as C- reactive protein,neutrophils proportion and blood sedimentation,the time of disappearance,such as cough,fever and lung wet rale and the clinical total effective rate were better than those in control group,presenting the significant difference( P < 0. 05). The difference in the incidence of adverse reaction was not significant between the two groups( P > 0. 05). Conclusion The integrated Chinese and western medicine achieves the significant clinical efficacy on infantile RMMP,has no apparent side reaction and is reliable in safety. Hence,this therapy deserves a further promotion in clinical application.
出处
《世界中西医结合杂志》
2016年第1期77-79,共3页
World Journal of Integrated Traditional and Western Medicine
基金
大连市科技局资助课题[辽科技合2008255号(08YJ38)]
关键词
中西医结合
小儿难治性肺炎支原体肺炎
安全性
Integrated Chinese and Western Medicine
Infantile Refractory Mycoplasmal Penumoniae Pneumonia
Safety
